{"id":"experimental-mxelox-plus-cetuximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Acneiform rash"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:12:48.391803","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mXELOX is a modified version of the XELOX regimen (capecitabine and oxaliplatin), a combination chemotherapy used in colorectal cancer. Cetuximab is a chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR) and blocks ligand-induced signaling, preventing tumor cell growth. Together, the regimen targets both DNA replication (via chemotherapy) and EGFR-driven proliferation pathways.","oneSentence":"mXELOX plus cetuximab combines modified capecitabine/oxaliplatin chemotherapy with an EGFR-targeting monoclonal antibody to inhibit tumor cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:02.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (likely EGFR-expressing, KRAS wild-type)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT05074966","phase":"PHASE3","title":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-09-06","conditions":"Colo-rectal Cancer","enrollment":314}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental: mXELOX plus cetuximab","genericName":"Experimental: mXELOX plus cetuximab","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mXELOX plus cetuximab combines modified capecitabine/oxaliplatin chemotherapy with an EGFR-targeting monoclonal antibody to inhibit tumor cell proliferation and survival. Used for Metastatic colorectal cancer (likely EGFR-expressing, KRAS wild-type).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}